Who Paid My Doc
Zostavax
Biological Vaccine
NDC 0006-4963-41
General payments
$3,835
Research payments
$2,047,746
Through program year 2024, $3,835 in general payments and $2,047,746 in research payments were reported against Zostavax (Vaccine).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $5,000 | 1 |
| 2023 | General | $257 | 11 |
| 2022 | General | $50 | 2 |
| 2022 | Research | $105,568 | 2 |
| 2021 | General | $1,063 | 1 |
| 2021 | Research | $758,368 | 3 |
| 2020 | General | $724 | 5 |
| 2020 | Research | $440,732 | 3 |
| 2019 | General | $1,741 | 98 |
| 2019 | Research | $738,079 | 4 |
Breakdown
The top 5 of 11 recipients; each share is of general payments naming this product in 2023.
Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2023 where a state was reported.
Records
117 general · 13 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.